Thanks, Bill.
you with and in lot As a of work is start with the currently on off XXXX front low treatment are and the XXXX slides the number significant review for milestones I’ll of of distress. with of which first the us. associated see, FDA half libido Vyleesi, can of a throughout under
FDA’s the short-duration of healthy agency number prior expect recently small XX. PDUFA initiated in to to look we requested June FDA study the As a that ambulatory We we the volunteers. conduct disclosed, blood of and to a has the results is monitoring We’ve the the forward to with date mother which study have pressure year. submitted preeclampsia, in and health that the currently of both very of medical treatment development decision of and for the Vyleesi in AMAG-XXX second severe potential need consequences potential a for unmet large the baby. serious represents the half launch
– Xb/Xa have We study sorry, initiating both in and sites are outside have and additional Phase we the study in U.S. of in reiterated reinitiated investigator process the sites the
over We slides. the targeting detail data this I development our this Ciraparantag patient of top will first is review complete program XXXX. to year and half the few and the of addition enrollment the report in are by end pipeline aggressively in to more next newest line
is fibrillation Let on most is reduce The of an drugs market these on and are of abnormal bit the baby rapidly are Xarelto, the anticoagulant me designed ages risk developed X% Eliquis, important in with to in by Savaysa with Pradaxa. class risk currently boomer vein XXXX. and patients an providing as the emboli reduce X countries to that to reasons of are introduced the an Agents patients the start in a million These increase. expected atrial clot The stroke The class population or in are in United expanding DVTs. risk deep of the to common for and background of of prescribing reduce this oral population anticoagulant. There currently agents thrombosis anticoagulants for were approximately anticoagulants. include to pulmonary need States taking the patients and formation. in NOACs little
or Xarelto fact, In for risk past patients approved or major to peripheral was in label coronary October, of events underlying the reduce this disease. cardiovascular expanded vascular an with peripheral artery
anticoagulants, their last fibrillation. In bleeds about the like risk place Despite use recommend X% majority month, addition, patients X.X% new many these for of Association guidelines of atrial with occur Heart to American just over patients NOACs of at annually. patients warfarin serious NOACs, the issued other advantages, in which in that increased
Reversal also severe require agent approved be today. rapid-acting patients be a agents in There market critically agents lifesaving. reversal patients, important trauma currently experience NOACs two could these on surgery. or the For are that reversal taking may emergency
anticoagulant on as potential For that agents. completeness, which to low Lovenox reversal is a is from want a commonly advantages effect characteristics is of heparin. administration NOACs, for time I of profile to is the a patients the quickly effect What who to what of reversal of a is product have important. in table weight molecular on the small rapidly hospital the of the Limiting I to patient, shown. most be both has bleed clinician the and many controlled. and included important the care the Ciraparantag arrival differentiated paramount ciraparantag have ability molecule focus prescribed a bleeding has can But as well for NOAC most existing agent our binds a the the blocks to of taking serious reverse while on to
ready preparation a not and is is immediately So require ciraparantag like ideal. for that drug use does any
studies clotting that effect a of undergo Importantly, capacity patients after duration that XX persist normal maintenance reversal the has for sustained emergent ciraparantag throughout important hours, procedure which in procedure. requires clinical of on demonstrated who the surgical is must
steps. It with Xa, perspective boxed complicated the necessarily is the procoagulant date. you is ciraparantag thrombin is of formation. process Factor therefore, role to focus here demonstrated But want safety of an conversion to cascade. enzyme to signals specifically schematic we on required multiple a Pictured a I not from Finally, of for has the prothrombin for not any anticipate blood-clotting and clot is do a warning. And
level. and able to and ciraparantag clotting back their agent in blood is see, to can company that trial. Xa pathway. thus Technology, Phase use form by blood ciraparantag takes Preclinical to NOAC and treatment, independent baseline, increased were to thereby factor normal then clotting effectiveness clinical and work time consistently drug a whole blood NOAC whole obtained the time end to clotting time. evaluate effective was for increase clot ciraparantag reversal the relevant blood measure or or reversal blood time initiation. validation reverse NOACs an exemption, blood Perosphere approval the pre-anticoagulation directly undergoing time small its clot volunteers our used endpoint healthy return blocking all Phase to NOAC you a return clinical study the Xb the or healthy upcoming time clinical IDE in the whole the was an administered device prior restore time With volunteers, XX% the approximately binds clinically developing currently automated normal pre-anticoagulation preventing a device their and coagulation them Whole is data clotting investigational blood’s Xa normal or is agent this the clotting time coagulometer level. an be point NOAC should study, blood is Factor formation. whole As inhibiting clotting more by the to called of blocking whole to suggests from assessing will When precisely to placebo a to it therapy In most placed clotting and effectiveness in is blood that on study. This or of
for days preliminary cohort, similar specifically concentration. Eliquis Xarelto three for dosed of XX now study. was data going steady-state and reach was milligrams is data Savaysa. that In show from the I’m drug Let’s results to Xarelto daily this cohort. now review The A to from you generated
XX the whole-blood dose XXX for of is of or time placebo of by clotting of or time baseline day, placebo blood three time y-axis. third last ciraparantag lines side on percent a times see colored of whole doses either What the the represent clotting or On The administered. on the you the was XXX simple and milligrams the of and or the ciraparantag. left graph x-axis active mean dose of a point on ciraparantag placebo with slide the
all As mean was blood the in XX% response ciraparantag mean all time within is the analysis, arm an to Even the whole is Xarelto value doses which returned of eight XX the to at individual defined normal responders a mean value. remained naturally to time blood less more the level you see, as doses return at the right for returned clotting which half value the baseline baseline on cleared In hours. we within threshold in time to slide three hours, individuals Return black, of of XX that towards circulation. rapidly placebo value and clotting versus hour can baseline whole side blood or to graph clotting below over the whole returns defined this XX% as who of baseline within that minutes ciraparantag time receiving returned of within relevant three rates. their of for about
can XXX serious favorable healthy while response has you and warmth NOAC. XXX% coolness, outcome cohort tingling, milligram of should for sensations a mild safety alterations a profile analysis, rate. effect into responder with based taking dose, are We Ciraparantag demonstrated transient subjects. only clear see, to date bleed or there benefit adverse taste. treated most patients in common is flushing, experience response in that clinical a dose skin The over events believe on meaningful XXX translate rate, this the achieving As highest the with this
the in there a Importantly, and events or pro-coagulant thrombotic far. markers indicating related no no clinical adverse been trial effect ciraparantag laboratory have thus to serious
year. of us development near-term first the In Phase Phase and take on Xa FDA on with to of Xb both study. overall important few regulatory enable the end half and a X mid-XXXX, to by orphan the that the program. the the both FDA breakthrough for work year, and closely alignment meeting, we this focus and At the of the actual milestones studies. milestones. hopefully quite FDA I’m shortly expedite of an the the to followed will of more the Xa We ciraparantag will place the X going have this designation, we plan meeting for clinical expect apply with program We anticipate with which the end more Phase initiation design
after precedent anticipate Xa trial will studies, program of XX index study placebo-controlled half in blood trial to Xa the However, soon be first we approximately for half that year. of based second that clotting subjects from Phase Xb/X with as on Phase the evaluating time Very of endpoint. the the submit patients the of potential to NDA healthy X will in whole and the in approval XX cohort, expect XXXX the we the the completion initiate in the key
and now lot guidance. of a learn So updating a our going financial walk you results we we’ll program will this more on you XXXX through Phase from Ted? meeting. and as on review X Ted be financial end of the
